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 Glioblastoma (GBM) is an aggressive cancer which presents significant challenges 
for disease management and treatment. Tissue sodium concentration (TSC) is a sensitive 
indicator of disease and changes in TSC can be used as a potential biomarker for treatment 
response. A longitudinal orthotopic C6 GBM model was used to study changes in TSC due 
to cancer. Animals were imaged with contrast enhanced T1-weighted, T2-weighted and 
sodium MRI and were either un-treated or received temozolomide (TMZ) treatment. 
Accurate assessment of TSC was possible for tumour volumes greater than 150mm3 using 
3mm isotropic imaging voxels. TSC increased with tumour growth for all animals. 
However, no differences in TSC were observed between treated and non-treated animals. 
This study demonstrates the feasibility of preclinical sodium MRI at 3T and highlights 
future potential challenges to overcome for this modality. 
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Summary for Lay Audience 
Glioblastoma (GBM) is an aggressive brain cancer which presents significant 
challenges for disease management and treatment. Tissue sodium concentration (TSC) is a 
sensitive indicator of disease and observing changes in TSC can provide additional 
information about tumour biology. Magnetic resonance imaging (MRI) is a powerful non-
invasive imaging modality which uses the physics underlying magnetism to obtain images 
of the body. MRI can capture the differences between soft tissues and provide detailed 
structural and morphological information about internal areas of the body. Standard MRI 
relies on the hydrogen atoms found in the body – particularly in the water to capture these 
images. Sodium MRI applies the same principles used in standard MRI but instead on 
sodium atoms found throughout the body, providing TSC information. In this study, C6 
rats were implanted with GBM brain tumours and imaged longitudinally using standard 
MRI techniques and sodium MRI. Animals were either untreated, or received treatment 
using temozolomide (TMZ) – the chemotherapy drug used to treat GBM. Accurate 
assessment of TSC was possible for tumour volumes greater than 150mm3 using 3mm 
isotropic imaging voxels. TSC increased with tumour growth for all animals. However, 
there were no differences in TSC changes between treated and non-treated animals. 
Ultimately TSC at endpoint was lower for treated animals, however this difference was not 
significant. This study demonstrates the feasibility of preclinical sodium MRI at 3T and 
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1 General Introduction 
1.1 Glioma 
Out of all tumours arising in the brain and central nervous system (CNS), gliomas 
are the most common [1]. In Canada, brain and CNS cancers are predicted to account for 
7.1% of all diagnosed cancers for 2020 [2]. Glioma is a general term used to describe 
tumours arising from glial cells and their precursors and include a variety of subtypes and 
grades [3]. Between 2009 and 2013 in Canada, tumours arising from these tissues 
accounted for over 80% of all diagnosed CNS tumours [4]. The World Health Organization 
(WHO) has released new classification criteria for gliomas, reclassifying them as an 
astrocytoma based on shared genetic markers. In this grading scheme, grades I and II are 
considered low-grade tumours, while grades III and IV are considered high grade. Current 
classification integrates both phenotypic and genotypic characteristics. In general, grade I 
glioma is the least malignant and can be treated through surgical resection. Grade II glioma 
is more infiltrative and more likely to recur and progress to higher grades. Grade III and 
IV gliomas are highly infiltrative and aggressive, and associated with poor prognosis and 
poor patient outcomes [5].  The following sections will expand on high grade gliomas and 
the challenges associated with their treatment. 
1.1.1 Glioblastoma multiforme 
Glioblastoma (GBM) are grade IV gliomas, the most aggressive and infiltrative. 
Cells from the main GBM tumour will migrate away from the main mass through the brain 





long distances, and potentially into vital regions of the brain. Since these diffuse cells can 
extend beyond lesions visible by imaging, it becomes more difficult to have a full grasp on 
the state of the disease. Furthermore, the location of GBM within the brain is often variable 
and can occur in areas difficult to treat, further compounding aggressiveness of this disease 
[6]. Additionally, GBM are also the most common malignant primary brain tumours, 
accounting for 45.6% of all gliomas and 15.4% of all primary brain tumours [7].  The Brain 
Tumour Registry of Canada reports that 12% to 15% of all intercranial tumours and 50% 
to 60% of astrocytic tumours are GBM. Median survival for patients is merely 12 to 15 
months after diagnosis and only 5% of patients survive to 5 years [8, 9]. GBM is 
heterogeneous and multiforme on a macro and micro scale. Overall, GBM tumours display 
regions of hemorrhage and necrosis, as well as regions of pleomorphic nuclei and cells, 
and microvascular proliferation [6]. GBM can arise as a primary tumour – wherein the 
cancer arises with no evidence of a precursor, or as a secondary tumour – developing from 
a lower grade diffuse astrocytoma [10].  
1.1.2 Glioblastoma therapy 
The clinical standard for GBM treatment is maximal surgical resection, followed 
by radiotherapy – 60Gy total split over 30 daily fractions of 2Gy each, concurrent with 
chemotherapy using Temozolomide (TMZ) – administered for 7 days at a daily dose of 
75mg/m2 [11].  However, despite this therapy, overall survival is still poor [8, 9]. 
Unfortunately, the median time to tumour recurrence is 8 months [5]. This rapid recurrence 
is likely because treatments cannot eliminate all the tumour cells [8]. Maximal surgical 
resection is limited by the diffuse nature of the disease; making it difficult to distinguish 





location in or near vital brain regions, and the rapid growth of the residual cancer stem cells 
after surgery [5, 6]. Radiotherapy is also limited by the diffuse nature of the disease, as 
targeted radiotherapy cannot hope to affect individual cells which have spread from the 
primary tumour. Chemotherapy effectiveness is limited by the blood brain barrier (BBB), 
restricting drug penetration into brain cells, and the heterogeneity of the cells, resulting in 
variable effectiveness [5, 8]. Upon GBM recurrence, treatment faces additional challenges. 
Surgery may not be possible after recurrence. Additionally, chemo- and radiotherapy 
options are limited at that point. In addition to no standard for second line chemotherapy 
in GBM treatment, the recurred tumour can acquire a chemo-resistant phenotype [1, 8]. 
Re-irradiation carries with it a risk of toxicity, as well as brain necrosis or radiation-induced 
injury [3, 8].   
1.2 Sodium and metabolism in biological tissues 
Sodium is the most abundant cation in the body and plays a key role in many 
cellular processes, such as nerve conduction, muscle contraction, and maintaining tissue 
osmolarity [12, 13]. Changes in sodium distribution within cells and tissues is associated 
with many pathologies. Sodium concentration (mol/L = M) is maintained at 10-15mM 
intracellularly and 140mM extracellular in healthy tissue [14]. This section provides 
background information about the role sodium plays in healthy tissues and the changes that 
occur in a cancerous phenotype. Changes in pathways regulating sodium form the basis for 





1.2.1 Tumour metabolism 
Sodium concentrations in the intracellular and extracellular space are carefully 
maintained for regulating proper cell function and volume [12]. The large sodium 
concentration gradient is maintained by a variety of active transport, voltage, and ligand 
gated channels. The most prominent transporter involved is the Na+/K+-ATPase or the 
sodium-potassium pump. This plasma membrane protein is expressed in most eukaryotic 
cells, and functions to maintain the sodium and potassium gradients. By using the energy 
from hydrolyzing adenosine 5’-triphosphate (ATP), the Na+/K+-ATPase transports three 
sodium ions out of the cell while pumping two potassium ions in, this enables healthy cells 
to maintain their low intracellular sodium levels [13]. Impairment of Na+/K+-ATPase 
function or cell membrane integrity can lead to an increase of intracellular sodium. Another 
important transported involved in sodium transport is the Na+/H+ antiport (NHE) or the 
sodium hydrogen antiporter. This membrane protein exchanges one intracellular hydrogen 
ion for one extracellular sodium. Of the NHEs, isoform I (NHE1) is expressed in most 
tissues and cells. NHE1 functions to maintain cytosolic pH as well as cellular volume [15]. 
The significance of sodium exchange acting to maintain intracellular pH is key to the 
Warburg effect that will be further discussed in section 1.2.2 and 1.2.3.  
1.2.2 Sodium ion flux in cells 
Healthy cells in a multicellular organism participate in controlled growth by heavily 
regulating their metabolic pathways. This is required as these cells receive a constant 
supply of nutrients. Control of metabolic activity prevents aberrant cell proliferation that 
exceeds nutrient availability. Healthy cells in aerobic conditions produce energy in the 





mitochondria [16]. Lactate is only produced in in anaerobic conditions. Cellular 
metabolism is altered in cancers, as cell survival and growth are promoted by 
circumventing oxidative phosphorylation to produce ATP through glycolysis even in 
aerobic conditions. The Warburg effect describes the tendency of cancer cells to ferment 
glucose to lactate regardless of oxygenation conditions, resulting in cancer cells 
undergoing aerobic glycolysis [17]. Aerobic glycolysis is much less efficient than oxidative 
phosphorylation in the production of ATP, however this process is virtually unregulated 
and in addition promotes tumour growth and proliferation. Tumours are effective in 
deriving the additional biomass needed for growth and proliferation from glycolysis 
because of the inefficiency of this pathway. Glycolysis produces numerous side products 
while metabolising glucose compared to oxidative phosphorylation uses all the available 
carbons in glucose to produce ATP [16]. This excessive production of lactate via aerobic 
glycolysis has implications for cellular health and homeostasis as lactate is transported out 
of the cells and used as biomass to further tumour growth [16].  
1.2.3 Sodium in cancer 
Excess production of lactate by aerobic glycolysis enables several malignant 
characteristics of cancerous cells. Due to the increase in proton concentration within the 
cell, intercellular conditions become acidic. To maintain cellular function, excess protons 
must be expelled from the cell. This results in extracellular acidosis as the protons begin 
accumulating outside of the cell. A heterogenous distribution of acidity, hypoxic 
conditions, and other environmental factors create the conditions to produce a highly 
heterogeneous tumour population that is malignant. The increase in proton concentration 





involved in the extrusion process, with the most prominent being the sodium proton 
antiporter (NHE1), a transporter upregulated in GBM [18]. This protein can be upregulated 
up to 15-fold over the expression level in human neural stem cells [19]. This channel 
exchanges protons for sodium ions on a one-to-one ratio. Over time, this action contributes 
to the increase in sodium concentration within the cell due to the accumulating sodium 
ions.  
Additionally, sodium concentration in the tumorous region can be affected by 
changes in the ratio between the intracellular and extracellular volume fractions. The 
extracellular volume fraction occupies a much smaller area than the intracellular space, but 
has a much higher sodium concentration [20, 21]. Increases in the extracellular volume 
fraction due to increased perfusion in the region, increased leaky vessels, or remodeling of 
the tumour micro-environment due to cancerous growth can cause overall tissue sodium 
concentration to also increase [21]. Overall, sodium concentration has shown to be 
increased in tumours and has potential to act as a biomarker for tumour growth [18, 22, 
23]. 
1.3 Pre-clinical GBM animal models 
Preclinical models are essential for the translation of research as they link the 
translation of in vitro cell based researched into clinical application and in vivo studies. 
These models allow researchers to test the applicability and translatability of their findings 
within a more complex system for the eventual hope of application into clinic or human 
settings. Preclinical models also find applicability in the testing of novel imaging 





new imaging modalities in preclinical models of disease lays the foundation for assessing 
the relevance of these new modalities for human imaging. 
Translatable imaging methods require animal models which can accurately 
recapitulate the biological interactions and clinical progression of human disease. 
Depending on the topic of study, different models will reproduce different aspects of the 
target biology. For preclinical GBM models of human gliomas the following features are 
desired: an approximating genotype, similar genetic, epigenetic, and phenotypic intra-
tumoral heterogeneity, and the development of a representative tumour micro-environment 
(including immune cell interactions, cell-cell interactions, and BBB) [25]. 
Animal models for the study of GBM have been developed for in vivo studies. The 
most common models used are small rodents, having multiple strains and species 
applicable to different purposes. Small rodent models can be generated in several ways, 
although cell-line derived models are the most common. Cell line-derived models rely on 
cancer inoculation using established, long-term in vitro cultured tumour cells. These cell 
lines can be transplanted into syngeneic hosts for allographic or xenographic (human-
based) models. In addition, cell-line cancer cells can be placed either ectopically, or 
orthotopically in its natural tissue of origin. Preference of model,  cell-line type, and 
location depends on which aspect of cancer biology is of interest [26]. For example, the 
U87 glioma is a human derived GBM cell line which has been used extensively for 
investigating tumour angiogenesis and anti-angiogenic therapies. However, this cell line 
fails to replicate key GBM phenotypes, such as diffuse infiltration, and a homogeneous 
appearance when imaged. Comparatively, the U251 glioma is also human derived, but 





line which can capture the genotypic and phenotypic characteristics of GBM improves the 
translatability of research which relies on these cell lines. Ideally, research would be 
conducted using patient-derived xenographs which could capture the complexities and 
nuances of GBM [28]. 
Of the available small rodent pre-clinical models, mouse models are most 
commonly used due to their ubiquitous use for genetic manipulation, having been used to 
generate a variety of immunocompromised strains which have been used with many cell-
lines [29-31]. However, there are two major considerations with these models. The first 
applies only to immunocompromised models using human cells, where the characterization 
of biological behaviour may be impacted due to the lack of tumour-immune cell 
interactions. Implantation in immunocompetent models allows for the study of tumour 
immunological characteristics, whilst implanting in immunocompromised animals allows 
for the evaluation of immunotherapies [32]. The second limitation is due to their small size, 
which limits their use for certain imaging applications as the spatial resolution needed for 
effective imaging could impact the signal-to-noise ratio (SNR) of the modality. With 
magnetic resonance imaging (MRI), this limitation can be overcome using high magnetic 
field strengths or using custom coils and gradient hardware [27]. 
Pre-clinical rat models are likewise a useful tool available for cancer models. 
Although most of these models are allogenic cell-line based due to the difficulty of 
producing immunocompromised strains. The major advantages of working with rat models 
include the greater accuracy for tumour implantation, as well as greater physiological 
similarities to humans, as compared to mice [32]. Several GBM cell-line models have been 





lines. The 9L gliosarcoma cell line has been the most widely used experimental rat brain 
tumour model, and has been used extensively to study chemotherapy and radiation therapy 
[27, 32]. However, considerations must be taken when using gliosarcoma as a model for 
GBM, as there are distinctions between the behaviour of these diseases [27, 33].  The F98 
glioma cell line is more representative comparatively, replicating human glioma invasive 
growth patterns and gene expressions, however F98 tumours resemble anaplastic gliomas 
more than GBM tumours [27, 34]. Of similar comparability is the C6 glioma cell line, 
which will be further described in the next section.  
1.3.1 C6 rat GBM models 
The C6 rat GBM cell-line was developed in the late 1960s in Sweet’s laboratory in 
adult Wistar-Furth rats though repeated administration of N-methylnitrosourea [27, 32]. 
This cell-line has been shown to have several histopathological similarities to human GBM. 
The cells are spindle shaped and pleomorphic with variably shaped nuclei, resembling 
human GBM cells [34]. Tumours generated from C6 cells in Wistar rats have been shown 
to have moderate foci of necrosis, with regions of focal invasion, nuclear polymorphism, 
and a high mitotic index [27, 34].  
The C6 cell-line has several genetic similarities to human gliomas as well, 
demonstrating similar changes in gene expression to human brain tumours. For example, 
both C6 and human GBM show frequent mutations in p16 – a common tumour suppressor 
heavily implicated to play a role in primary brain tumour development [27, 35]. 
Specifically, C6 cells have been reported to have a mutated p16/Ckn2a/Ink4a locus, with 
no expression of p16 and p19 adenosine diphosphate (ADP) ribosylation factor (ARF) 





include the wild type p53 that C6 cells possess [27]. Additionally, C6 cells have lack of 
glial fibrillary acidic protein – a common diagnostic marker for GBM in humans [37], and 
variable expression of vimentin – a cytoskeleton protein that has been associated with 
metastatic disease and the progression of GBM [38].  
Typically, C6 cells can be implanted and grown in Wistar rats, but they have been 
implanted in the Sprague-Dawley and Long-Evans strain without rejection [27]. However, 
it should be noted that C6 tumour growth in Sprague-Dawley and Long-Evans differs 
greatly from growth in Wistar rats, approximating brain metastasis growth behaviour with 
reduced infiltration and without parenchymal invasion. When implanted inside the Wistar 
rat, the growth pattern of C6 more closely resembles its human counterpart. In addition, 
the immune micro-environment of the C6 tumour resembles human GBM [34]. It is 
important to note there exists a level of immunogenicity in response to the tumours within 
Wistar rats, such that C6 cells cannot be used for assessing immunotherapies [27]. Despite 
this, C6 tumours are extremely well studied and have been used to study tumour growth, 
cell invasion and migration, tumour angiogenesis and BBB disruption. In addition to 
mirroring the biology, C6 cells also mirror imaging characteristics of  human gliomas – 
making it especially useful in imaging studies [34].   
1.4 Clinical imaging of GBM 
Monitoring and assessing tumour progress is very important in GBM disease 
management and treatment. Non-invasive imaging methods for evaluating disease 
progression and treatment response form the basis for decisions to alter or abandon the 





anatomical imaging modalities such as 1H MRI, x-ray computed tomography (CT), or 
positron emission tomography (PET).  
These modalities are used to provide insight into brain anatomy, structural 
abnormalities, tumour location and degree of spread, and in some cases, functionality. The 
current standard for brain tumour imaging is MRI, either with or without contrast 
enhancement, or CT if the patient is unable to undergo MR imaging (due to a pacemaker 
or other magnet sensitive implants) [40]. If available, PET has been recommended and 
used as an additional clinical diagnostic assessment tool evaluating functional 
characteristics of the tumour, with glucose metabolism tracers and amino acid transport 
tracers being used predominantly [41].  
The following section describes the use of MRI for monitoring GBM in greater 
detail, as well as examining the advantages and challenges associated with the modality.   
1.4.1 Magnetic resonance imaging 
There are a variety of MRI sequences available for anatomical imaging. Two- (2D) 
or three-dimensional (3D) imaging data sets can be acquired with different endogenous 
contrasts depending on the parameters selected. Typically, T1-weighted, T2-weighted and 
contrast enhanced (CE) sequences are used to evaluate GBM as the presence of the tumour 
influences the image contrast by modifying the underlying tissue structure [42]. Imaging 
with MR provides the most value in early disease detection and guiding intervention. The 
gold standard for diagnosing and monitoring GBM is brain MRI. Typically, gadolinium 
(Gd) CE MRI is used, as glioma lesions tend to show contrast enhancement in T1-weighted 





anatomical images with high sensitivity but limited specificity [43]. Serial imaging with 
MR has revealed several prognostic features which have been associated with patient 
survival outcomes, such as edema – associated with poor prognosis, and non-contrast 
enhancing tumour – associated with longer survival [42, 43]. Additionally, research into 
advanced MR sequences have been able to discern various features characteristic of GBM. 
Techniques such as diffusion weighted imaging, dynamic susceptibly contrast enhanced 
perfusion imaging, and MR spectroscopy have been used in research to study GBM 
progression and treatment response [44-46].  
Given the current gold standard of GBM monitoring and diagnosis, several major 
challenges exist. Firstly, there are numerous non-neoplastic conditions which can mimic 
gliomas on neuro imaging such as: brain abscesses, subacute stroke, or other inflammatory 
diseases. In many cases, these conditions may also mimic similar symptoms. Therefore it 
is essential to not solely rely on brain MR for GBM diagnoses [40]. Monitoring treatment 
effect on GBM using MR presents additional challenges. Pseudo-progression and pseudo-
response are the major confounding factors in GBM monitoring. Pseudo-progression is 
what appears as an increase in contrast enhancement and/or edema without true tumour 
progression. The appearance of pseudo-progression is most commonly associated with MR 
imaging after treatment with concomitant radio- and chemotherapy with TMZ followed by 
disease stability or lack of clinical progression [43]. Pseudo-response is what appears as a 
decrease in enhancement without true anti-tumour effect and is generally associated with 
anti-angiogenic therapies [43]. This occurs due to reduced delivery and retention of the 
contrast enhancement agent in cancerous region, resulting in a decrease in contrast 





from imaging artefacts and differential treatment response. Failing to identify these 
pseudo-phenomena can lead to premature termination of effective therapies, unnecessary 
surgical interventions, or the use of additional treatment agents [3].  Unfortunately, pseudo-
progression is a relatively common phenomenon and has been observed in up to 50% of 
all patients with GBM in their first post-therapy MR scan 2-3 months following chemo-
radiotherapy [47, 48]. Pseudo-progression can be induced by a variety of causes related to 
the treatment itself including inflammation, ischemia, and radiation-induced necrosis [3, 
49]. Radiation necrosis can appear as a single “lesion” at the resection site which can appear 
as a recurrent tumour. In areas far from the primary tumour, necrosis can mimic multifocal 
lesions [49]. As this pseudo-phenomenon often presents after treatment, this limits the 
application of CE MRI for post-surgery evaluation, as the pooling of fluids or vascular 
damage results in CE that does not reflect the true disease state. Discriminating between 
pseudo-progression and true progression is difficult since conventional MR cannot 
differentiate the two. Additionally, pseudo-progression can resolve spontaneously, which 
can mislead observers to believe that the treatment is effective [50]. This spontaneous 
resolution is likely due to healing of the BBB and clearing of edema from the area which 
reduces CE in the region [51]. Identification of pseudo-progression is imperative as 
diagnosis can influence the choice to either continue with adjuvant therapy or change to a 
second-line therapy [39, 52]. While MRI continues to be the most accessible and powerful 
modality for evaluating tumour progression, such limitations necessitate development by 





1.4.2 The Macdonald criteria  
The current most widely used guideline for evaluation of response to therapy in 
high grade gliomas is the Macdonald criteria [52]. The Macdonald criteria was established 
in the 1990s and has been widely adopted since [42]. Evaluation of glioma by the 
Macdonald criteria relies predominantly on 2D anatomical tumour measurements from 
consecutive post-Gd T1-weighted MRI scans concurrent with clinical assessment and 
corticosteroid dosing [52, 53]. This allows for evaluation of neurological symptoms and 
the use of corticosteroids to target tumour-induced edema [54].  
According to the Macdonald criteria, high grade glioma tumours are assessed based 
on changes in the largest cross-sectional area from consecutive post-Gd T1-weighted 
images obtained at least 1 month apart [53]. The cross-sectional area measurement is 
obtained from the product of the largest cross-sectional diameter and the largest diameter 
perpendicular to it. Tumour response is classified into one of four categories: complete 
response (CR), partial response (PR), progressive disease (PD), and stable disease (SD). 
The imaging evaluation criteria for CR is the complete disappearance of enhancing disease 
on consecutive MRI scans at least one month apart. A classification of PR requires a greater 
than 50% reduction in the size of the enhancing tumour on consecutive MRI scans and no 
new lesions. A classification of PD requires a greater than 25% increase in the enhancing 
tumour size, or the appearance of new lesions. Lastly, SD consists of scenarios which do 
not fall into any of the above [53].  
The widespread adoption of the Macdonald criteria and the advent in imaging 
technology and therapeutics has revealed many areas where the current measures lack 





been criticized for its ambiguity for defining appropriate thresholds for lesion size and lack 
of detail in how to apply the criteria [42]. Critically, the scope of the Macdonald criteria 
does not address the challenges of pseudo-progression and pseudo-response. This is largely 
due to how heavily the criteria relies on Gd-enhanced images. It is also important to note 
the limitations inherent in the tumour measurement technique, where the maximal 
perpendicular diameters in the contrast enhanced tumour are used to calculate a cross-
sectional area. This measurement method has limitation application in irregularly shaped 
tumours and can be subject to inter-observer variability [55].  
Contrast enhancement in tissues relies heavily on vascular permeability. This can 
severely limit its applicability in non-vascularized tumours and when used in conjunction 
with anti-angiogenic drugs [56]. Additionally, contrast enhancement for glioma in post-
treatment brain is non-specific and cannot be considered a true measurement of tumour 
response but rather the integrity of the BBB [52]. Enhancement can also be confounded by 
a variety of factors, including radiation necrosis, inflammatory response, edema in the 
surrounding tissues, changes in corticosteroid doses, and radiological technique. This 
makes changes in contrast enhancement subject to many factors and thus limits 
interpretation as changes in enhancing area cannot be directly equated to changes in tumour 
size [55].  
1.4.3 Response Assessment in Neuro-Oncology 
The Response Assessment in Neuro-Oncology (RANO) criteria was introduced in 
2010 to address the limitations of the Macdonald Criteria [50]. While the criteria are 
currently largely used for clinical trials, it is the current gold standard for evaluation of 





criteria introduced assessment for non-enhancing areas of the tumour and critically focused 
on identifying pseudo-progression [39]. The RANO criteria utilizes T2-weighted and fluid-
attenuated inversion recovery (FLAIR) imaging in addition to Gd-enhanced MR images as 
part of the imaging criterion for response assessment. The usage of T2-weighted and FLAIR 
imaging produce tumour contrast without the use of agents and allow for identification of 
changes in non-enhancing areas [55].  
Like the Macdonald criteria, the RANO criteria also uses the cross-sectional area 
produced by the maximal perpendicular diameters in the contrast enhancing area [55]. For 
measurable disease, the diameters must be obtained from CT or MR scans with clearly 
defined margins. Diameters must be at least 10mm and visible on two or more axial slices 
at most 5mm apart. Disease is considered unmeasurable when lesions do not have clearly 
defined boundaries and diameters less than 10mm. Unlike the Macdonald criteria, RANO 
also introduces measures for multifocal lesions – where at least the two largest lesions 
should be measured. In cases of high grade gliomas a maximum of five of the largest 
lesions should be measured [55, 56].   
The RANO criteria also divides tumour response into CR, PR, PD, and SD criteria. 
Where basic imaging criterion for CR is defined as no enhancing disease for 4 weeks and 
stable or improved T2-weighted/FLAIR visible lesions; indicated by minimal changes or 
reduced lesion size. Criteria for PR requires ≥ 50% decrease in enhancing lesion size with 
stable or improved T2-weighted/FLAIR lesions and no appearance of new lesions. Criteria 
for PD requires a ≥ 25% increase in enhancing lesion size, increased T2/FLAIR lesion size 
and/or appearance of any new lesions outside the radiation field [39]. There are also 





tumour progression within the first 12-weeks post-radiotherapy occurs if most of the new 
enhancement occurs outside the radiation field or with histological confirmation [3, 42]. 
However, practices for evaluating progression within the radiotherapy field requires MR 
changes to persist for at least 4 weeks before being definitively confirmed [3].   
Despite the improvements RANO has made to previous criteria, limitations still 
exist. Although non-enhancing regions are taken into consideration using T2-weighted and 
FLAIR imaging, changes in the non-enhancing regions can occur due to treatment, surgery, 
or radiotherapy [42]. The addition of non-contrast enhanced criteria is limited by the lack 
of objective imaging parameters resulting in subject interpretations and high adjudication 
rates [3, 56]. RANO is still limited as it still uses bidirectional measurements of contrast 
enhanced tumour size. This method of measurement has been shown to overestimate 
tumour volume and results in higher reader discordance due to the challenges of identifying 
the longest perpendicular diameters in irregularly shaped tumours [56]. Additional 
limitations are presented in the arbitrary thresholds for defining response and progression 
– as the use of thresholds based on percentage change from baseline are biased towards 
small tumours as small changes in absolute tumour size result in large percentage changes 
[56].  
Currently, RANO still remains the gold standard for assessing tumour response in 
GBM. Although limited in several aspects, it improves significantly upon the previous 
Macdonald criteria and introduced new criteria for addressing pseudo-progression and non-






1.5 Basics of magnetic resonance imaging 
Magnetic resonance imaging (MRI) is a versatile modality used for medical 
imaging. It provides superior contrast between soft tissues compared to other modalities 
such as CT or ultrasound (US). MR imaging can produce 2D and 3D images with 
differential contrasts. This allows for identification of abnormalities or diseases that may 
appear differently under different imaging conditions.  
Standard MRI uses a strong, homogeneous magnetic field to induce nuclear 
magnetization in hydrogen atoms associated with water molecules and fat in the subject. 
The magnetic field is generated by a superconducting magnet which can be used to generate 
magnetic fields on the order of Teslas (T). Comparatively, a fridge magnet averages around 
1mT. Fields strength is often associated with specific imaging applications. Scanners used 
in clinical settings can range between 1.5T to 3T. Scanners used for research purposes can 
have field strengths ranging up to 21.1T [57]. However, most commonly these high-field 
research scanners will range from 7T to 10T [58]. 
This section will provide a general overview of the physics governing magnetic 
resonance image formation and factors affecting image contrast.  
1.5.1 Nuclear spin and magnetization 
The foundation of MRI relies on nuclear magnetic resonance of a nucleus of 
interest. Traditionally, the proton is the nucleus of choice due to its high in vivo 
concentration (80M) and high MR sensitivity due to its magnetic dipole moment [59]. 
Nuclei that can undergo magnetic resonance must have a non-zero spin and hence, a 





magnet in space. Typically, these magnetic dipoles are randomly oriented, resulting in a 
net-zero magnetization as the magnetization cancels over the volume for a large ensemble. 
However, in the presence of a large external magnetic field (𝐵0⃑⃑⃑⃑ ) – such as the field 
generated by an MRI, the magnetic dipoles precess around 𝐵0⃑⃑⃑⃑  . The distribution of angles 
in the cone of precession is almost uniformly distributed between 0° and 180°, with a slight 
preference for smaller angles with increasing field strength. This results in a net 
magnetization (𝑀0⃑⃑ ⃑⃑  ⃑) which underlies the source of the MR signal (Figure 1-1.) [60].  
By convention, the direction of 𝐵0⃑⃑⃑⃑  is used to define the Z-axis of a Cartesian 
coordinate system. The rate of precession of the protons for a given 𝐵0⃑⃑⃑⃑  depends on the 
nucleus of interest and the strength of B0 and is described by the Larmor frequency (𝜔0) 
as defined by equation 1.1 [59].  
𝜔0 = ?̅?𝐵0 (1.1) 
Figure 1-1. Illustrative schematic showing orientation of magnetic dipoles in the 
presence of a large external magnetic field (𝐵0⃑⃑⃑⃑ ). Magnetic dipoles preferentially align 





Where ?̅? is the gyromagnetic ratio; an intrinsic characteristic of MR sensitive nuclei 
which describes the magnetic dipole strength. The gyromagnetic ratio for some common 
nuclei is listed below in Table 1-1.  
The 𝑀0⃑⃑ ⃑⃑  ⃑  of a volume can be affected by several factors. Including the number of 
magnetic nuclei per unit volume, the magnetic moment of these nuclei (as described by ?̅?), 
and 𝐵0⃑⃑⃑⃑ . MRI is practically limited by the sample magnetization which limits the speed of 
image acquisition and achievable image resolution. Imaging of hydrogen protons is 
ultimately made feasible by the combination of these factors as the concentration of protons 
in soft tissue is approximately 80M and 62% of all nuclei in the body are protons [59]. 
Moreover, imaging of non-hydrogen nuclei (X-nuclei) must overcome these challenges to 
present with useful MR signals. These challenges will be detailed further in section 1.6.   
To detect MR signal, 𝑀0⃑⃑ ⃑⃑  ⃑ must first be rotated away from its position along the Z-
axis through the action of a second oscillating magnetic field (𝐵1⃑⃑⃑⃑ ) generated by a transient 
radiofrequency (RF) pulse. This field oscillates at the Larmor frequency in the XY plane 
perpendicular to the Z-axis. The B1 field excites or “tilts” 𝑀0⃑⃑ ⃑⃑  ⃑ away from the Z-axis to some 
desired angle, after which is it turned off. The angle that 𝑀0⃑⃑ ⃑⃑  ⃑ is tilted is known colloquially 
as the flip angle (𝛼). For example, for an 𝛼 of 90°, 𝑀0⃑⃑ ⃑⃑  ⃑ would rest completely in the XY 
plane. Following the transient RF excitation 𝑀0⃑⃑ ⃑⃑  ⃑ will begin to relax or “decay” back to its 
Table 1-1. Gyromagnetic ratios (?̅?) of some commonly imaged nuclei. Of these, 1H is 





original position along the Z-axis. The amplitude of the magnetizations’ projected 
components over time characterize different relaxation profiles. The amplitude of the 
magnetization in the XY-plane decays from a maximum to a minimum, while the 
amplitude of the magnetization along the Z direction recovers back to its original value. 
The decay of the magnetization in the XY plane and the regrowth of the magnetization 
along the Z-axis are known as the transverse and longitudinal relaxations respectively. 
Contrasts between tissues in MR relies on the differences in relaxation profiles from 
different tissues [59]. These concepts of relaxation, contrast, and signal detection will be 
further expanded upon in following sections. 
A B 
Figure 1-2. Illustrative schematic showing the behaviour of the net magnetization (𝑀0⃑⃑ ⃑⃑  ⃑) 
under (A) excitation by an external field (𝐵0⃑⃑⃑⃑ ). Grey arrows show the direction of 
movement of the 𝐵1⃑⃑⃑⃑  and 𝑀0⃑⃑ ⃑⃑  ⃑. (B) Shows the behaviour of 𝑀0⃑⃑ ⃑⃑  ⃑ after being tilted away 
from the main magnetic field (𝐵0⃑⃑⃑⃑ ). Dotted lines show the longitudinal and transverse 





1.5.2 Transverse magnetization and relaxation 
The transverse magnetization is the component of 𝑀0⃑⃑ ⃑⃑  ⃑ projected into the XY plane. 
This magnetization holds its largest amplitude immediately after all the magnetization has 
been flipped into the transverse plane after an 𝛼 of 90°. Over time, this component will 
decay to zero as 𝑀0⃑⃑ ⃑⃑  ⃑ precesses around 𝐵0⃑⃑⃑⃑ . This decay is exponential with time, t and is 





Where T2 is the transverse relaxation time constant, an intrinsic characteristic of the 
material being imaged. In vivo, T2 values are tissue specific and can differ based on tissue 
type and composition [59, 61].  
Transverse relaxation (also known as spin-spin relaxation) occurs due to a 
dephasing of the precessional phases of individual constituent magnetic dipoles in the 
tissue. This reduces the net amplitude of the transverse magnetization. Dephasing occurs 
more rapidly in a non-uniform magnetic field as different field strengths occurring across 
an imaging voxel will result in different local precessional frequencies. The T2
*, also known 
as the effective T2 accounts for this field inhomogeneity and is also affected by other 
external factors such as system imperfections, tissue/air (or tissue/metal) interfaces, and 
blood oxygen levels. This effective T2 is always shorter than the intrinsic T2 value of tissue 
[59]. The impact of T2
* can be overcome through MR sequence design, particularly by 





1.5.3 Longitudinal magnetization and relaxation 
The longitudinal magnetization is the component of 𝑀0⃑⃑ ⃑⃑  ⃑ along the Z-axis. Overtime, 
this component exponentially grows from a minimum back to the original 𝑀0⃑⃑ ⃑⃑  ⃑ value. This 
growth can be characterized by the following equation [61]. 




Here T1 is the longitudinal relaxation (also known as the spin-lattice relaxation) time 
constant, or the characteristic time taken for the magnetization vector to realign with the 
direction of B0. When 𝑀0⃑⃑ ⃑⃑  ⃑ has been tilted to 90
o, the longitudinal magnetization component 
is zero, but begins to grow back through longitudinal relaxation. Like transverse relaxation, 
longitudinal relaxation rates differ depending on the tissue. By convention, the T1 value of 
a specific tissue is defined as the time taken for the longitudinal relaxation to reach 63% of 
its final value assuming a 90o pulse is used [59].  
1.5.3.1 T1 contrast agents 
T1 contrast agents find their use in MR imaging by increasing the specificity of MR 
contrast. These agents have magnetic properties which manipulate the T1 of tissue in their 
vicinity and increases the differences in signal between tissues at specific T1 times. Contrast 
enhancement occurs due to shortening of the targeted tissue’s T1 values. This increases the 
signal of the target tissue while the background signal remains the same when imaged with 
a MR sequence with T1 contrast weighting. Enhanced relaxation occurs due to strong dipole 
interactions between the proton magnetic dipole moment and that of unpaired electrons in 





typically lanthanide compounds (such as gadolinium) which require chelation due to 
concerns over metal toxicity. The chelation allows the hydrogen protons in water molecules 
to get close to the paramagnetic agent for dipole-dipole interactions but prevents absorption 
of the toxic agent within the body. Gd-based contrast agents are typically delivered through 
an IV bolus with arterial enhancement lasting for a few minutes. Generally, the contrast is 
non-specific and could depend on the vascular perfusion in the region of interest [58, 62]. 
1.5.4 T1 and T2 weighted imaging 
The intrinsic differences among T1 or T2 values in different tissues underlies the 
ability of MRI to distinguish soft tissues. Sequence design for MR imaging takes advantage 
of these differences to produce images with different contrasts. The typical MRI sequence 
consists of a series of RF pulses repeated over time, known as a pulse sequence. In a 
standard pulse sequence, there is a specified period between RF excitation and when signal 
acquisition begins. This time is known as time-to-echo, or TE. This gives the tilted 𝑀0⃑⃑ ⃑⃑  ⃑ a 
Figure 1-3. Pre (L) and post (R) gadolinium contrast enhanced images of the rat head 
from a coronal view. Enhancement can clearly be seen in the region of the tumour and 





period to relax. As mentioned above, this relaxation occurs at different rates for different 
tissues in vivo. Ideally, when signal acquisition begins, the differences between the 
magnetization of different tissues are maximized, generating contrast between them. 
Optimal choices for TE depend on the contrast weighting of the image, and the area being 
imaged. An additional factor to consider is the time between each pulse sequence 
repetition, known as the time-to-repeat or TR. This is the time between each excitatory RF 
pulse. Adjusting this time allows for the magnetization to relax to a desired state before 
repeating the pulse sequence. Variation of TE and TR provide the basic methods to adjust 
image contrast. T1-weighted images can be obtained using pulse sequences with short TEs 
and short TRs. Under this contrast, fluids will typically appear darker while fattier tissues 
will appear brighter. T2-weighted images can be obtained with long TEs and long TRs. 
Under this contrast, fluids will typically appear brighter and fats tissue will appear darker 
[59].  
1.5.5 Spin-density weighted imaging 
A less commonly imaged MR weighting is spin-density weighted imaging, also 
known as proton density or nuclear density weighted imaging. In this weighting, the 
contrast between tissues relies solely on the number of magnetically resonant nuclei within 
the volume and tissue of interest. This produces contrast that is proportional to the 
concentration of nuclei. With brighter areas having more MR sensitive nuclei than darker 
areas. These images can be obtained using pulse sequences with long TRs and short TEs. 
The long TR allows the T1 of the tissue to recover to the original value, removing T1 effects. 
The short TE minimizes T2 effects as decay is minimized [59, 62]. In X-nuclear imaging, 





that reflect the T1 and T2 values of those nuclei in tissues. This provides a method to 
interrogate the concentration of the X-nucleus within the volume of interest. This type of 
X-nuclei imaging has been used to investigate 19F and 23Na in vivo as molecular imaging 
probes [13, 63]. 
1.5.6 Spin echo imaging 
The spin echo pulse sequence is a versatile sequence which uses a 90° excitatory 
RF pulse followed by at least one 180° pulse. This sequence can be used to produce spin 
density, T1-, and T2-weighted images. The main characteristic of the spin echo is the 180° 
“refocusing” pulse. This pulse results in rephasing of the transverse relaxation components 
into an “echo” allowing for more signal acquisition. For a conventional spin echo sequence 
at 1.5T, typical parameters for T1-weighted images are TE=20ms and TR=500ms. Typical 
parameters for T2-weighted images are TE=80ms and TR=2000ms [59].  
Fast spin echo (FSE) imaging improves on the conventional spin echo sequence by 
reducing scan time. This is done by repeating the 180° refocusing pulse with signal 
acquisition following each inversion, allowing for multiple readouts to be obtained within 
one TR. The echo train length (ETL) parameter describes how many echoes are to be 
acquired in one TR, with imaging time inversely proportional to ETL. The rapid imaging 
achievable by FSE and the ability to produce many different image weightings make FSE 
one of the most useful MR pulse sequences [62].  
1.5.7 Introduction to RF technology 
The main tool for MR imaging is the RF coil. These coils are the source of the 





are designed to generate a uniform oscillating electromagnetic field. Most often, this is the 
RF coil incorporated within the MRI bore known as the body coil. To transmit RF energy 
to excite a particular nucleus, Tx coils must produce an electromagnetic field that oscillates 
at or near 𝜔0 for that nucleus. Additionally, the field must oscillate in a plane perpendicular 
to the main field of the magnet to facilitate excitation of 𝑀0⃑⃑ ⃑⃑  ⃑. The amount of RF energy 
required to excite a particular nucleus is determined through the transmit gain (TG). This 
parameter determines how much energy is needed to induce a 90° flip angle and is used to 
calibrate all other flip angles specified. Values for TG can depend on the subject imaged, 
coil type, and sequence used. Often, the excitatory RF pulse is transmitted by one coil, and 
the resultant MR signal is received by another coil. This allows for simpler RF coil designs 
and when used together with transmission by the body coil of the MRI, allows for more 
uniform excitation over the entire volume. However, it is also possible for a single coil to 
serve both the Tx and receive (Rx) functions. This type of coil can reduce whole body 
exposure to RF induced heating, allows for acquisition of more slices, and reduces artefacts 
from tissues outside the volume of interest. Challenges that face Tx/Rx coils are the more 
complex coil designs required, and reduced B1 field uniformity over the volume of interest 
[62, 64].  
The resonant frequency of the RF coil depends on the inductance (L) and 
capacitance (C) of the components in the circuit. This is the frequency where the coil works 
most efficiently for RF transmission and/or reception. Typically, the resonant frequency of 
the coil can be tuned by adjusting capacitors placed along the conducting loop. Tuning 
ensures that the coil efficiently responds to signal over a very specific frequency range. 





of the nucleus of interest at a specific field strength. As seen in equation 1.1, 𝜔0 depends 
on the main field of the magnet, meaning a hydrogen proton in a 3T system precesses at a 
different frequency from a hydrogen proton in a 1.5T system or any other MR-visible 
nucleus at the same field strength [58, 62]. 
Coils are available in a variety of geometries which can serve different imaging 
needs. The most common are birdcage coils, surface coils, and solenoids. Birdcage coils 
and surface coils will be discussed in greater detail. Of these geometries, the birdcage coils 
are perhaps the most ubiquitous owing to their versatility and reliability. This coil geometry 
can be used for Tx/Rx and creates a uniform excitation and SNR within its bore, making it 
very useful for 3D imaging. The surface coil has the simplest geometry and can often exist 
as a simple loop. This type of coil can be used to interrogate very specific regions of the 
body, and as this coil is able to be shaped to the region of interest, an SNR increase can be 
observed as noise from outside of the sampled area is filtered [64]. However, this comes at 
the cost of imaging volume and signal falls off as distance from the surface of the coil 
increases. Surface coils perform best when the coil size is close to the size of the imaged 
object. Unfortunately, its 2D geometry results in a non-uniform receive profile. Images 
produced from a surface coil tend to have high SNR near the coil surface with rapid signal 
fall off as distance from the coil increases. Correction pipelines are often used to correct 
for non-uniformity in images from surface coils [65]. Surface coils can be arranged into an 
array, which extends the volume of useable SNR of a single small surface coil. This allows 
for imaging with a surface coil with high sensitivity over a larger volume [62].  
There are additional challenges faced by surface coils with Tx/Rx capabilities. 





presents a major challenge. Due to the asymmetry of excitation, as RF energy increases, 
the region in the coil where nuclei are flipped 90° shifts throughout the sample volume. 
This can be ameliorated with a reference marker and shift reagent. A shift reagent is a 
molecule which can affect the magnetic field experienced by certain nuclei, and thereby 
shift the precession frequency of that nucleus. The amount of frequency shift the nuclei 
experiences depends on the reagent and its concentration in the solution with the nuclei of 
interest. Frequency shifts to the tune of a thousand Hz are possible [66]. When an RF coil 
tuned to a specific nucleus is used on a subject and a shift reagent solution, two MR signal 
peaks will be detected. One peak will belong to the 𝜔0 of the nuclei within the subject, 
while the other peak results from the impact of the shift reagent. If this shifted peak is 
distinct and well resolved from the subject peak, it can be used as a reference for setting 
the RF energy input into the system. By placing the shift reagent solution in a known and 
consistent position, RF energy input can be evaluated for this reference point across 
multiple imaging sessions. When used in conjunction with a surface coil, reproducible 
excitation profiles can be generated [64, 66].  
Despite different coil geometries, MR signal is usually received in the same way. 
After excitation, the resulting precessing transverse magnetization induces a voltage in the 
RF coil. This voltage oscillates at the Larmor frequency with an amplitude that decays 
exponentially with a time constant given by T2*. It is this voltage signal that is amplified 






1.6 Sodium magnetic resonance imaging 
As discussed previously in section 1.2, tissue sodium levels are significantly 
impacted in cancer and other diseases. Sodium is one of the two endogenous nuclei suitable 
for human MRI [21]. Changes in total tissue sodium concentration (TSC) as measured by 
sodium MRI (23Na MRI ) are more sensitive to disease changes on the molecular level in 
conditions like cancer, stroke, or multiple sclerosis compared to proton MRI [67]. This 
section will provide background on the techniques and challenges associated with imaging 
sodium using MRI. 
1.6.1 Sodium MRI 
Nuclei suitable for MRI require a magnetic dipole moment formed from a non-zero 




allowing it to present a detectable MR signal. However, the nature of the sodium nucleus 
presents challenges specific to its nuclear characteristics. Magnetic resonance signals also 
depend on ?̅?  and the in vivo concentration of a nucleus. The signal in MRI is approximately 
proportional to 𝛾3. Given that the ?̅? of sodium is only 11.262MHz T-1 compared to 
42.577MHz T-1 for 1H, the available sodium signal is significantly less than the available 
proton signal. Additionally, the average in vivo TSC between the intra- and extracellular 
environments is approximately 40mM [67]. Comparatively, the average concentration of 
water-associated protons is 80M. Combined, these factors make the sodium signal much 
smaller and more difficult to detect compared to proton (~30,000 times lower) [14]. 
However, nearly 100% of sodium in vivo exists as the MR sensitive isotope, meaning most 








 nuclear spin has implications for the behaviour of the sodium 
signal. In addition to a magnetic dipole moment, sodium has an electric quadrupolar 
moment that interacts strongly with the electric field gradients in its environment. In 
addition to dipole interactions, these quadrupolar interactions cause the sodium nucleus to 
exhibit biexponential T2 relaxation. The T2 relaxation of sodium has a slow component 
(T2,slow ~15–30ms) and a fast component (T2,fast ~1–5ms) owing to its biexponential nature. 
The T1 relaxation of sodium is mono-exponential but is also rapid at ~30-40ms [14]. The 
range of these relaxation values also depends on the tissue of interest. Within the brain, 
white matter and grey matter have relaxation times that differ from cerebral spinal fluid 
(CSF) [13]. These relaxation values are listed in Table 1-2. 
To maximize acquired sodium signal, 23Na MRI requires specialized hardware and 
software. Custom RF coils tuned to the 𝜔0 of sodium and an MR system fitted with 
broadband transcieve capabilities are required to image sodium. In addition, sequences for 
sodium require ultrashort echo times (UTE) less than 0.5ms. These sequences also typically 
acquire at low resolutions with short excitation RF pulses to minimize sodium signal loss 
and maximize SNR [70]. Overall, sodium imaging sequences require longer acquisition 
times and more averages to obtain high SNR. However, there are technical limits regarding 
how long a subject can be imaged due to subject motion and equipment stability. Therefore, 
Table 1-2. Sodium relaxation times for human brain tissues in vivo. These ranges are based 





efficient sequence design is necessary for clinical applications. Details regarding 23Na MRI 
sequences will be expanded in the following section. 
1.6.2 Sodium imaging sequences 
Sodium imaging sequences prioritize maximizing SNR to overcome the inherent 
limitations of imaging sodium in vivo. MR sequences designed with UTE in mind aim to 
avoid the short T2 effects associated with the sodium nucleus and allows for quantitative 
23Na MRI [21]. Ideally, this TE needs to be shorter than 0.5ms to detect both T2 components 
of sodium [13]. One of the methods used to minimize TE is the adoption of a radial k-space 
encoding scheme rather than Cartesian. In Cartesian k-space encoding, a phase encoding 
gradient and frequency encoding gradient are required, which in essence allow the MR 
signal to be read out across the plane line by line. However, there is no signal acquisition 
during the time needed for the phase encoding gradient – resulting in undesirable losses in 
SNR when imaging sodium.  
Sodium imaging sequences like 3D projection reconstruction (3DPR) and twisted 
projection imaging (TPI) use a radial encoding scheme. These methods apply a short, hard 
excitation pulse, followed by radial gradient trajectories to acquire from angular 
projections (3DPR) or spiraled trajectories (TPI). The 3D encoding gradient eliminates the 
need for phase encoding gradients as the MR signals can be read outwards from a central 
point. These sequences are able to shorten TE significantly compared to phase encoded 
sequences [21]. A traditional 3DPR imaging scheme relies on these constant radial 
projections to fill in k-space. However, it’s limited by over-sampling in the central regions 
of k-space (low-spatial frequency) and under-sampling in the edge regions of k-space 





overcomes this limitation of 3DPR. Rather than reading the MR signal out in straight lines 
from center out, the readouts for this scheme follow varied spiral like trajectories to 
uniformly sample k-space producing high SNR images. However, TPI is limited by its 
complex implementation and high hardware demands [21, 70].  
A different imaging scheme that is based on 3DPR is the density-adapted 3DPR 
(DA3DPR) sequence. This sequence can match the SNR efficacy of TPI without the 
hardware demands. The main improvement DA3DPR makes on traditional 3DPR imaging 
is overcoming the non-uniform k-space sampling. Ultimately this sequence requires many 
trajectories to fully cover all of k-space to satisfy the Nyquist sampling criterion. Overall 
DA3DPR imaging has been demonstrated to acquire images with increased SNR and 
reduced blurring [72].  
1.6.3 Tissue sodium concentration 
There are different ways to interpret the sodium MR signal, with considerations for 
each. The sodium signal can be measured quantitatively, either as TSC or the intracellular 
sodium concentration, given as an absolute sodium concentration measurement in mM 
[21]. The intracellular concentration is of particular interest because of its sensitivity to cell 
viability and ion homeostasis, which are implicated in disease states in neurodegenerative 
diseases [14]. TSC is a weighted average of the intracellular and extracellular sodium 
compartments [67]. This is different from obtaining measurements of the intracellular 
sodium concentration specifically. Isolating sodium compartments requires significant 





It is also possible to quantify the sodium signal by looking at changes in the signal 
intensity. However, this method has some limitations owning to possible differences 
between acquisitions as signals can be confounded by non-uniform spatial distributions of 
the flip angle (𝛼). Therefore, maintaining the same spatial distribution of 𝛼 between scans 
is important for accurate measurements [21]. Ultimately these methods of sodium 
quantification are possible as they are based on spin-density weighted imaging, made 
possible by sodium sequence designs.  
1.7 Project aims and hypothesis 
The aim of this thesis was to conduct a preliminary study investigating treatment 
effects using sodium MRI. A DA3DPR sodium imaging sequence was implemented for 
quantitative small animal imaging at 3T and 23Na MRI for examining longitudinal 
treatment response in pre-clinical models of GBM was investigated. Implementation and 
optimization of the DA3DPR sequence for quantitative small animal sodium imaging was 
evaluated using a curved butterfly surface coil. The optimized sequence and imaging 
protocol were used to evaluate longitudinal changes in TSC in a preclinical rat model of 
GBM. Proton (T2, pre- and post-contrast T1) and sodium images were acquired and co-
registered to evaluate changes in tumour growth and total tissue sodium concentration over 
time.  
It was hypothesized based on the biological relevance of sodium in tumour biology, 
that significant changes in TSC would be observed in response to treatment with TMZ. 
Treatment with TMZ can affect sodium levels in tumours through cell death – which can 





increased sodium levels due to increases in the extracellular volume fraction [20, 73]. 
Specifically, it was hypothesized that TSC in the tumour region would decrease with 
treatment due to the decrease in metabolism. It is important to recognize that the DA3DPR 
sequence used for this imaging is only sensitive to total TSC and cannot differentiate 
between intracellular and extracellular compartments. Therefore, the expected changes 
would be dependent on the combined changes of sodium concentration within the cells and 
in the surrounding extracellular space.  
The goal of this work was to investigate the potential for sodium as an MR 
biomarker for tumour response that could be more specific than current clinical criteria. 
This could potentially improve on the challenges faced when imaging GBM and the impact 
these challenges have on treatment and patient response.  
 1.7.1 Challenges of COVID-19 
Over the last 16 months, we have been faced with unprecedent challenges in the 
form of the COVID-19 global pandemic which greatly impacted our ability to conduct pre-
clinical research. In addition to delays caused by research shutdowns, many new obstacles 
with regards to accessing resources and personnel needed for experimental procedures 
arose after we recovered from the first wave. From new scheduling systems for space 
access to difficulties booking training sessions  ̧many factors contributed to challenging 
progress. This thesis was ultimately able to be brought to fruition with the support of the 
Animal Care and Veterinary Services team in the middle of the pandemic. Additionally, 
support provided by fellow lab members, my supervisor, as well as the university helped 
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2 Materials and methodology  
2.1 RF Hardware 
To facilitate co-registered proton and sodium imaging, two separate radiofrequency 
(RF) coils were utilized: a proton birdcage RF coil and a curved sodium surface coil. The 
RF coils were designed such that the curvature of the sodium surface coil could fit snugly 
within the bore of the larger cylindrical proton birdcage coil. This would allow for co-
registered images to be acquired and for the coils to be moved relative to each other.  
Proton imaging was conducted using a custom-built 8-rung birdcage coil and RF 
shield. The dimensions of the cylindrical acrylic tube for the coil was 88.9mm in outer 
diameter (OD) with a form thickness of 3.2mm and 264mm in length. This tube had two 
outer nylon rings used to locate an RF shield concentrically about the RF coil. The 
dimensions of the shield were 356mm long with an 165mm OD. The loaded resonant 
frequency of this coil was tuned to 127.74MHz, the Larmor frequency of water protons at 
3T.  The Q factor for the birdcage coil was 200 [1]. The sodium images were obtained 
using a custom-built rectangular butterfly surface RF coil constructed on a cylindrical 
former with a diameter of 55.65mm. The dimensions of each surface coil were 47.86mm 
by 78.92mm and the coils were overlapped by approximately 15.66mm. Both channels on 





concentration of 50mM filling the entire coil imaging volume. Figure 2-1 shows the image 
of the sodium coiled used.  
2.2 Imaging phantoms 
Custom imaging phantoms were constructed to evaluate the performance of the 
sodium RF hardware, imaging sequence, and intensity correction pipeline. Cylindrical 1% 
agarose phantoms were produced that matched the curved form of the surface coil. This 
method allowed for the phantom to completely mold to the shape of the coil and fill the 
entire imaging region. The phantoms were chosen to have a sodium concentration of 
50mM, based on average physiological sodium concentrations [2]. 
2.3 DA3DPR protocol optimization for sodium MRI 
Sequence evaluation and imaging was performed on a GE Discovery MR 750 3.0T 
MRI (General Electric Healthcare, Milwaukee, WI, USA) [3]. The DA3DPR sequence was 
provided by Dr. Akbari as described in Nagel et al. [4]. Sodium imaging was evaluated 
with two coil configurations: imaging with sodium coil alone and imaging while the proton 
birdcage was placed around the sodium coil. Imaging was performed at 1mm and 3mm 
isotropic resolution for evaluation of the imaging SNR. Imaging at 1mm resolution was 
Figure 2-1. Sodium surface coil shown from (L) a top-down view and (R) down the 





performed with the addition of an insertable gradient coil. Since excitation and encoding 
gradients were activated at the same time, greater accuracy is required, especially 
considering the radial encoding scheme which is more sensitive to imperfect gradients than 
Cartesian schemes [5]. Accuracy was hindered by eddy current issues which resulted in 
artifacts. Additionally, it was observed that 1mm voxels did not produce enough SNR to 
obtain measurable TSC in tissue in a reasonable amount of time. To achieve useful imaging 
SNR within a reasonable imaging session, it was evident that 1mm isotropic resolution 
would be challenging, and 3mm isotropic resolution was chosen for the in vivo 
measurements of tissue sodium concentration (TSC).  
Imaging protocols at 3mm isotropic resolution were optimized with the addition of 
a “shift agent”, thulium-1,4,7,10-tetraazacyclododecane 1,4,7,10-tetrakis(methylene 
phosphonate) (Tm-DOTP5-) to a sodium reference vial [6]. The purpose of doping a 
phantom with a shift reagent is to change the resonant frequency of the 23Na nucleus in 
contact with the reagent. This “frequency-shifted” reference vial was used as a reference 
marker in a known and consistent location across longitudinal imaging sessions. This 
produced a well resolved second signal peak from the sodium inside the tube. This peak 
could be used to determine the amount of RF energy needed to excite the magnetization of 
the sodium nuclei through 90° at a repeatable position with respect to the RF coil. The 
sodium peak from the imaging subject itself could not be used as within the imaging space 
of the surface coil, increases in TG could alter the distribution of 𝛼 within the space. This 
would be inconsistent between subjects and it would be difficult to reliably reproduce the 
same excitation profile across different imaging sessions. Data reported by Winter et al. 





the sodium nucleus. In conjunction with tests using solutions of different concentrations, a 
shift of 1000Hz was achieved given the solubility limits of Tm-DOTP5-. A solution of 
200mM of Tm-DOTP5- and 2M NaCl solution was used as a reference peak for setting 
transmit gain (TG) for the surface coil. By implementing the reference marker in a single 
repeatable location for all longitudinal imaging sessions, a consistent and replicable 
excitation profile can be achieved with a surface coil. The shift reagent reference tube 
(75.85mm length by 11.42mm diameter) was placed in a defined position at the center of 
the imaging region of the coil. The shifted peak was confirmed visually on the scanner and 
TG was determined from the maximum observed amplitude of the shifted peak. This 
reference tube was then removed prior to beginning sodium image acquisition.   
2.4 Cell culture 
C6 rat glioma cells (CCL-107, American Type Culture Collection, Manassas, VA, 
USA) were cultured in Dulbecco’s Modified Eagle Media (DMEM) (Wisent, Montreal, 
QC, CA) containing 10% fetal bovine serum (FBS), 1% antibiotic-antimycotic and 
supplemented with 4-times concentration of non-essential amino acids and 2% L-
glutamine. Cells were grown at 37°C in 5% CO2. Cells were evaluated for mycoplasma 
using the MycoAlert Mycoplasma Detection Kit (Lonza, Basel, Switzerland). 
2.5 Animal model 
An orthotopic glioma model was used for this study. On day 0, 200-250g male 
Wistar rats (Charles River Laboratories, Wilmington, MA, USA) underwent stereotactic 
surgery for cell implantation into the brain. Fur on the superior side of the rat head was 





surface and bregma and lambda were landmarked and horizontally leveled.  A 2.5mm burr 
hole was drilled 1mm posterior and 3mm right-lateral to bregma. A 25G Hamilton 
microliter syringe (Hamilton 700 series) was advanced to a 4mm depth and used to inject 
106 C6 glioma suspended in 10L of phosphate buffered solution (PBS) at a rate of 
3L/min. The needle was left in place for 1 minute before extraction. The surgical site was 
flushed with a sterile saline solution to wash away any cells which may have effused from 
the injection site through the burr hole. Finally, bone wax was used to fill the burr hole to 
block any additional cells from effusing. Animals were imaged on days 7, 10, 12 and 
imaged every 3rd day after that except for rat 1. This animal received imaging on days 7, 
10, and then every 2nd day after that. When tumours reached a volume of greater than 
150mm3, animals were designated to: first a control group which received no therapy (n=4) 
and followed by a treatment group (n=3). The treatment group received 40mg/kg of 
Temozolomide (TMZ, Sigma Aldrich, Miamisburg OH, USA) dissolved in dimethyl 
sulfoxide (DMSO, Sigma Aldrich, Miamisburg OH, USA) via intra-peritoneal injection 
for 5 consecutive days. At endpoint, animals were perfused, and tissue was collected for 
histological examination. All animal procedures were conducted in accordance with 
relevant guidelines by the University Council on Animal Care and the Animal Use 
Subcommittee (AUP 2018-164). 
2.6 In vivo imaging 
 2.6.1 Sodium imaging 
Animals first underwent imaging with the sodium surface RF coil which allowed 





with the proton birdcage RF coil. The sodium coil was positioned on an MR compatible 
tray comprised of a curved cylindrical acrylic former suspended from plastic rails. This 
configuration placed the animal head near the isocentre of the MRI bore as well as allowed 
for the placement of a proton birdcage RF coil and shield around the animal without any 
additional repositioning of the animal (Figure 2-2). Solutions with sodium concentrations 
of 30mM, 50mM, 70mM, and 100mM in 2mL reagent bottles were placed along the 
underside of the coil. These reference vials were used for the correction of the RF coils 
sensitivity profile and to determine absolute TSC. 
All animal imaging was conducted on a GE Discovery MR 750 3.0T MRI (General 
Electric Healthcare, Milwaukee, WI, USA). A detailed image showing the imaging setup 
is shown in Figure 2-3. Sodium imaging was conducted using a density-adapted 3-
dimensional projection reconstruction sequence (DA3DPR) (TE=0.5ms, TR=100ms, 
Taq=8ms, flip angle (𝛼)=90°, FOV=80mm isotropic, NEX=10, imaging time=12mins) [1]. 
The transmit gain for imaging was set based on a vial of 200mM Dm-DOTP5- and 2M 
Figure 2-2. An illustrative schematic showing the positioning of the proton birdcage, 
sodium surface coil and animal position down the vertical axis. The proton birdcage is 






sodium chloride solution placed in the center of the coil’s imaging area. This solution 
produced a sodium signal peak with a shifted frequency of approximately 1000Hz [2]. 
Images were reconstructed using a custom MATLAB script (MathWorks, Natick, MA, 
USA) to an imaging matrix size of 27 × 27 × 512 with 3mm isotropic imaging voxels. 
2.6.2 Proton imaging 
To acquire proton images, the proton birdcage coil and shield were slid onto the 
rails and positioned to be concentric with and centred on the sodium coil.  For each imaging 
session 3D T2-weighted images and 3D pre- and post- gadolinium-DTPA (0.5mmol/kg; 
Magnevist, Bayer, Leverkusen, Germany) contrast enhanced (CE) T1-weighted images 
were acquired. The T2-weighted images were obtained using a 3D fast spin echo sequence 
(FSE) (CUBE, General Electric Healthcare, Milwaukee, WI, USA) with the following 
Figure 2-3. A photograph showing a typical set up for sodium imaging. The sodium 
coil and animal in supine position are placed on a specially constructed tray which 
suspends an acrylic half-pipe between the rails. Anesthesia and heating can be placed 
around the animal. The halfpipe is slid through the bore of the proton coil which is 
centered by nylon end-rings to position it along the rails. This allows the proton coil to 





parameters: FOV=60mm isotropic, acquisition matrix=128×128, slice thickness=0.5mm, 
bandwidth=62.50MHz, NEX=3, TR=2432ms, TE=60ms, echo train length (ETL)=120, 
imaging time=12 minutes. The T1-weighted images were also obtained using a general 3D 
FSE sequence with the following parameters: FOV=60mm isotropic, acquisition 
matrix=128 × 128, slice thickness=0.5mm, bandwidth=31.25MHz, NEX=1, TR=281ms, 
TE=18.2ms, ETL=10, imaging time=10 minutes. Post-CE images were acquired 30s after 
Magnevist (Bayer, Leverkusen, Germany) injection.  
2.7 Image processing 
2.7.1 Intensity correction and quantification 
Sodium images were reconstructed using MATLAB (MathWorks, Natick. MA, 
USA), GE Orchestra (General Electric Healthcare, Milwaukee, WI, USA) and the 
Michigan Image Reconstruction Toolbox (Jeffery A. Fessler, “Michigan Reconstruction 
Toolbox”, web.eecs.umich.edu/~fessler/code/). Sodium images were reconstructed into an 
imaging matrix volume of 27 × 27 × 512 with 3mm isotropic imaging voxels. To prepare 
images for intensity correction, ITK-SNAP  (www.itksnap.org, [7]) was used to perform 
region of interest (ROI) segmentations. The subject and sodium reference vials were 
segmented from the background noise using ITK-SNAP’s built-in semi-automatic 
segmentation tool. The mask generated from this segmentation was used with a custom 
MATLAB script (MathWorks, Natick. MA, USA) for purposes of correction of the non-






Figure 2-4. Schematic showing the major steps and outputs in intensity correction 
pipeline. 1) An intensity normalized sensitivity axial image of a 50mM 1% agarose 
cylindrical phantom with four 50mM reference vials along the bottom. Acquired with 
30 averages 2) A segmented and intensity corrected image of a 50mM 1% agarose 
phantom with 30mM, 50mM, 70mM, and 100mM reference vials along the bottom. 3) 
A linear regression formed through a plot of known sodium concentration in the 
segmented reference vials versus the average signal intensity in the segmented reference 
vials. The line is used to remap signal intensities in the image to their corresponding 
concentration. Error bars represent standard deviation of pixel measurements in each 
reference vial. 4) Final image and reported average concentrations ± SD after intensity 
remapping showing the 50mM phantom and reference vials along the bottom. 
Measurements in small ROIs range from 47.9 ± 2.7mM to 51.5 ± 1.6mM. The average 
± SD across all 6 sample ROIs was 49.5 ± 2.5mM. 5) Showing the ROI selection (blue) 
within the volume of the phantom (red) rendered from segmentations take in ITK-SNAP. 






To correct for intensity variation over the imaging area of the surface coil, a high SNR 
image containing only sodium intensity variation was obtained by using a 50mM 1% 
agarose phantom and 50mM reference vials. This sensitivity map was normalized to then 
obtain a normalized sensitivity map which could be used to scale intensities in an in vivo 
image. To process an in vivo image, a mask of the areas of interest (main area to be 
corrected and reference vials) was made using the semi-automatic segmentation tool in 
ITK-SNAP. This mask was eroded to address observable partial volume effects (PVE), 
especially in the edge regions of the reference vials. The average noise in the image was 
calculated from an averaged background ROI and then subtracted from each pixel to 
address the offset across the imaging volume which improves the precision of the 
quantification. Sensitivity correction was obtained by dividing the subject image by the 
normalized sensitivity map which adjusts pixel intensities to account for the signal fall off.  
Using the normalized sensitivity map, areas close to the surface of the coil are typically 
divided by larger numbers while areas further away from the surface of the coil would be 
divided by smaller numbers. This would offset the intensity fall of due to the surface coil.  
To quantify sodium measurements from the intensity corrected image, first the 
average intensities from the known reference vials were extracted. These intensity values 
were mapped against their known concentrations to determine a line of best fit. This line 
was used to remap the pixel intensities across the rest of the image to concentration values. 
This pipeline was validated through the quantification of known 40mM and 80mM saline 
phantoms which were used to fill the imaging volume. This was followed by in vivo 
validation by evaluating healthy brain TSC in rats and comparing these values against 





session. Images were processed as described in section 2.6.2 and whole brain 
segmentations were obtained to determine the TSC of the healthy brain.  
2.7.2 Image analysis  
Manual registration of sodium and proton images was achieved using rigid linear 
transforms in 3D Slicer (www.slicer.org, [8]). Additionally, sodium images were 
resampled into the same voxel spacing as the proton images. Measurements for tumour 
volume from T1- and T2-weighted images were obtained from manual segmentations in 
ITK-SNAP (www.itksnap.org, [7]). Tumour boundaries from T1-weighted images were 
determined based on post-CE images. T2-weighted anatomical proton images were used as 
a guide to manually segment the tumorous regions to determine tumour TSC values from 
sodium images for each animal in the experiment. 
As a comparison, matched baseline “contralateral” sodium measurements for each 
animal, a tumour free region in the posterior portion of the brain – far away from where 
the main tumour would grow was segmented out for measurement. Additional TSC 
measurements from healthy, tumour-free animals were obtained using the same 
registration methods. Whole brain segmentations were used to determine average healthy 
brain TSC. 
2.8 Endpoint histology 
At experimental endpoint, animals were euthanized and perfused with 4% 
paraformaldehyde (PFA) in PBS. The whole brain was then extracted and stored in 4% 
PFA at 4°C for 24 hours. After fixation, brains could be placed in PBS at 4°C for long term 





For cryo-sectioning, brains were placed in solutions of increasing sucrose 
concentration (10%, 20%, 30%) until fully sunken to extract water content. After which 
the brain would be embedded in optimal cutting temperature (OCT) medium and frozen on 
dry ice before moving to long term storage at -20°C. Ten-micron sections were obtained 
using a microtome-cryostat (Leica CM1860, Wetzlar, Germany) and stained for 
hematoxylin and eosin (H&E). Whole-mount sectioned slices were scanned using the 
EVOS imaging system (M7000, ThermoFisher Scientific, Waltham, MA, USA). 
2.8 Statistics and analysis 
Statistical analyses were performed using GraphPad Prism v8 (GraphPad Software 
Inc., California, USA). A two-way ANOVA and Tukey’s post hoc was performed to 
investigate endpoint TSC. Exponential growth curve fitting was performed to model 
tumour growth based on tumour volume measurements over time. This relationship was 
then used to determine the tumour growth rates. Linear regressions were performed to 
identify any trends in the between measures and Pearson correlation analyses were 
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3 Results and analysis 
3.1  Results 
To evaluate sequence performance and optimization, image quality from different 
DA3DPR acquisition protocols were evaluated. Comparisons between 1mm isotropic and 
3mm isotropic imaging resolutions showed that overall SNR was higher using the 
insertable gradient system compared to the clinical gradient system. Qualitative 
observation indicated that sodium MR image quality at 3mm imaging resolution was higher 
than at 1mm imaging resolution, as expected. Sequence implementation using the 
insertable gradient system introduced new artefacts and challenges regarding feasibility as 
unwanted image artefacts such as blurring, and ringing were common. Additionally, 
hardware limitations were encountered due to the sensitivity of the radial sequence to eddy 
currents and gradient imperfections. As a result, in vivo imaging was acquired without the 
gradient insert system.  
 To optimize the addition of the shift reagent Tm-DOTP5- for 3mm imaging 
resolution in vivo at clinical settings, a simulation of shift reagent concentration to reported 
frequency shift based on past literature was created. The final concentrations of 23Na and 
TmDOTP5- were determined by considering the amount of sodium for a well-defined peak 
and the solubility limits of TmDOTP5- in water. Figure 3-1A shows the final observed peak 
which has been shifted approximately 1300 Hz from the main sodium peak. The 
combination of the DA3DPR sequence and the shift reagent was used to image a 50mM 





SNR of 14.9 could be achieved for images averaged 10 times (imaging time=12 minutes). 
A representative axial slice of a cylindrical phantom filling the imaging volume is shown 
in Figure 3-1B. It should be noted, an asymmetric signal profile was observed from the coil 
upon image reconstruction. This asymmetry was not observable from the bench and is 
likely to be the result of something further down the receive chain. This asymmetry did not 







Figure 3-1. (A) 23Na FID spectrum showing the (L) shift reagent signal and (R) signal 
from 50mM 1% agarose cylindrical phantom with frequency centered on shift reagent 
peak. (B) Representative axial slice of a cylindrical 50mM 1% agarose phantom 









Figure 3-2. (A) Single representative animal from the non-treatment group. Bottom 
panel shows a zoomed in view of sodium images overlayed onto T2-proton weighted 
images at longitudinal time points. Tumours are outlined by yellow boundaries. (B) 
Graph of average tissue sodium concentration ± SD for representative animal for both 
the tumorous region and contralateral brain region. (C) Side-by-side H&E histology, 
T1-weighted image, and sodium image of non-treated animal at endpoint. Tumours are 






A total of 7 rodents were monitored using longitudinal sodium imaging at multiple 
time points post-implantation. These animals were split into control (n=4) and treatment 
(n=3) groups. Figure 3-2A shows a representative animal’s sodium, proton and overlaid 
sodium and proton MR images while the animals’ representative TSC measurements over 
time are show in Figure 3-2B. A visible increase in the area and concentration of TSC 
localized to the tumour can be observed starting from day 12. T1-weighted proton images 
Figure 3-3. Graph of average tissue sodium concentration ± SD for (L) tumour and (R) 
contralateral tumour-free region for all imaging time points. Top row shows all animals 
and bottom row averages all cohorts to obtain a linear regression for all animals. Dotted 
lines show the 95% confidence interval. The slope for TSC versus time for the combined 
tumour group was significantly different from zero (p<0.05) and not significantly 
different from zero for the combined contralateral brain group (p=0.15). Slopes for the 






and sodium images are also shown next to a corresponding H&E histology slide in Figure 
3-2C. This shows the correspondence between the histological tumour area and what can 
be observed from the imaging data. The boundaries of the tumour are clearly visible and 
well defined in the T1-weighted images, however the reduced resolution (3mm isotropic) 
in the sodium images show a lack of similar definition. Figure 3-3 shows the longitudinal 
changes in TSC across all animals in both control and treatment groups. Increasing TSC 
over time can be observed in the tumours while TSC in the contralateral brain stays 
relatively constant for both the control and treatment groups. The increase in TSC over 
time in the tumour has a slope significant from zero (slope = 1.16 ± 0.21mM/day, 
p<0.0001). The slope of TSC versus time in the contralateral brain regions is not 
significantly different from zero (slope = 0.23 ± 0.16mM/day, p=0.15).  
Contrast enhanced T1-weighted imaging was acquired for 5 animals out of the total 
7. Animals in both treated (n=3) and non-treated (n=2) cohorts received CE MRI. 
Although T1-weighted imaging is typically used in clinical imaging, our model saw the 
volume measurements from the T2-weighted images better captured the bounds of the TSC 
distribution.  Overall, there was more inhomogeneity in T1-weighted images, which could 
be indicative of necrosis or changes in the permeability of the blood tumour barrier. 
Tumour morphology from T2-weighted images were found to better correlate with tissue 
sodium distribution compared to T1-weighted images, especially in control animals. This 
was qualitatively confirmed by visible inspection at endpoint by histology. The volume 
difference between the T1-weighted and T2-weighted measurements was on average 350.4 
± 123.18mm3 for control animals at endpoint. An example of this discrepancy can be seen 





Figure 3-5 shows the tumour volumes extracted from the T2-weighted proton 
images plotted against the average TSC measurements from the tumours for both groups. 
Average tumour TSC increased with volume for both non-treated and treated animals. 
However, the rate of this increase did not differ significantly between groups (p=0.42). A 
vertical line indicating a volume of 150mm3 is included as that is the volume where reliable 
quantification of sodium signal localization to the tumour was possible. This represents 
approximately six sodium imaging voxels for our TSC imaging. Overall, average tumour 
volume at endpoint in the control group trended higher than in the treatment group, 
however this difference was not significant. 
Figure 3-4. Representative animal showing a sagittal view of the brain (from left to 
right: T1-weighted post-CE, T2-weighted, sodium MRI images). Outline shows the 
boundaries of the tumour as taken from the T2 volume also overlayed on the same 
position in the T1-weighted post-CE and sodium images. Image resolution for the above 





Figure 3-6 shows tumour growth rate derived from volume measurements plotted 
against average TSC. A positive correlation between growth rate and average tumour TSC 
for both control (r=0.78) and treatment cohorts (r=0.67) was observed. The slope for this 
relationship did not differ significantly between groups (p=0.57). The range of growth rates 
observed in the control group is larger than the range of growth rates observed in the 
treatment group. The maximum growth rate in the control group is 265.8±0.1mm3/day 
while the maximum in the treatment group is 136.2±0.2mm3/day. This error was obtained 
from the 95% confidence interval. The uncertainty in the difference of these two rates is 
129.6±0.3mm3/day.  As this difference is represents greater than 4 standard deviations, the 
difference between the growth rates are significant.  
Figure 3-5 Graph of average tissue sodium concentration for (L) non-treated and (R) 
treated for measured tumour volumes. Dotted lines show the 95% confidence interval 
for the linear regression. Slopes of average TSC versus tumour volume were not 






The relationship between time after injection and ΔTSC between the tumour and 
contralateral brain showed that differences between brain region did not significantly differ 
depending on cohort and overall trended in a positive direction. It was observed that overall 
differences in TSC between the tumour region and contralateral brain increased. Lastly, a 
A 
B 
Figure 3-6. (A) Graph of average tissue sodium concentration in tumours for (L) non-
treated and (R) treatment cohorts for tumour growth rate. Dotted lines show the 95% 
confidence interval for the linear regression. Slopes not significantly different at a 95% 
confidence level (p=0.57). (B) Graph of average doubling time of tumour volumes for 






comparison of TSC at endpoint across treatment groups and brain regions showed that 




Figure 3-7. Graph of ΔTSC between tumorous region and contralateral brain for time 
matched points for (L) untreated and (R) treatment cohorts. Dotted lines show the 95% 
confidence interval for the linear regression. Slopes are not significantly different at a 







Figure 3-8. Graph of average TSC ± SD at endpoint for the tumorous region and 
contralateral brain region. Differences between brain region are significant for both non-
treatment and treatment groups (p<0.0001). Average tumour TSC (p=0.59) and average 
contralateral brain TSC (p=0.84) at endpoint were not significantly different between 























































In this study we demonstrated the first implementation of DA3DPR sodium 
imaging to study an orthotopic glioblastoma tumour model in rats at 3T. The sequence was 
successfully implemented at 3T using the clinical gradient. In addition, sodium images 
from the surface coil imaging was successfully quantified using our inhouse algorithm. The 
implementation of this sequence with the addition of a proton birdcage which slid over the 
sodium setup meant that anatomical images could be intrinsically co-registered with 
sodium images. Our preliminary study showed that the imaging protocol was sensitive to 
changes in TSC over time and in different brain regions. In the clinic, CE T1-weighted 
imaging and T2-weighted imaging are typically used to assess glioma. A combination of 
T1-weighted and T2-weighted proton anatomical images with sodium MRI images allowed 
for the investigation of the relationship between TSC and the physical characteristics of the 
tumours, such as volume and growth rate. Sodium MRI could additionally add molecular 
information about glioma for this preclinical model.  
The segmentation based on the anatomical images allowed for the extraction of 
tumour volumes and TSC. Based on tumour volume measurements and observable signal 
localization, sodium signal can be reliably quantified for tumour volumes larger than 
150mm3. Tumour volume was a limiting factor in sodium quantification due to the voxel 
size in the sodium scans, thus diffuse areas of the tumour or offshoots of the main mass 
which can be visualized in the proton scans cannot be detected in the sodium. Voxel size 
will likely continue to be a limiting factor in sodium MRI studies as most studies report an 
isotropic resolution of around 2.5mm3 in both preclinical and clinical settings [1-4]. It 





and therefore longer imaging durations. The analysis showed that TSC increased over time 
within the tumours as they grew. Increases in tumour growth rate were additionally 
correlated with increasing TSC. Ultimately this indicates that the sodium imaging protocol 
is supported by anatomical imaging as TSC was extracted based on the observable tumour 
from T2-weighted images. Based on the co-registration and segmentation, changes in the 
TSC could be observed specific to the tumour. This analysis revealed that this sodium 
imaging method and animal model did not show differences in the tumour TSC between 
control and treatment group animals. A few studies have investigated long-term trends in 
pre-clinical models using sodium MRI and clinically relevant proton sequences, thus the 
insights provided by this study provide valuable insight into possible trends and 
considerations for further studies of this type [5]. 
An evaluation of growth rate determined from the longitudinal segmentations 
showed there was an increase in tumour volume doubling time observed for animals in the 
treatment cohort. This difference is not significant therefore it is difficult to say whether 
treatment influenced the rate of growth of the tumours. This could explain the similarities 
in the TSC values for both cohorts. It should be noted that the range of growth rates was 
greater for control animals than the range of growth rates for treatment animals, which may 
indicate treatment influenced tumour growth which was not reflected in the TSC. This 
could partly be owed to the differing durations of survival between cohorts. The 
chemotherapy regiment was aggressive and animals in the treatment cohort deteriorated 
rapidly compared to animals in the control cohort. As a result, overall survival times for 
the treatment cohort were shorter.  Ultimately it is unclear if the lack of differences were 





A key measurement evaluated was the time matched difference between TSC in the 
tumour and TSC in the contralateral brain (ΔTSC). These differences increased over time 
as we observed increases in the tumour TSC compared to the relative steadiness in the 
contralateral brain TSC. It is important to recognize that the contralateral brain is not a 
perfect measurement of baseline TSC to evaluate changes against. As it is in the same organ 
as the tumour, this region is not healthy and is affected by the extracellular tumour 
environment. Inflammation, infiltration, and extracellular environment changes are 
potential factors that could affect the contralateral side [6]. These changes, in particular 
inflammation would result in TSC increases which may explain the observed upwards 
trend [7]. It is also likely that the chemotherapy had some effect on the cells in the 
contralateral brain. TMZ is not a targeted therapy and specifically functions via DNA 
alkylation, therefore all dividing cells in the body would be affected to some degree and 
cell death is likely to increase in the healthy dividing glial cells in the brain [8]. Therefore, 
the slight increase in TSC over time observed in the contralateral brain may point towards 
a combination of these described factors. We are interested in the contralateral region 
despite these limitations as it is within the same organ as the tumour and can therefore 
present the most relevant point for comparison.  
We incidentally observed that regions of high TSC better correlated with tumour 
boundaries observed in T2-weighted images rather than T1-weighted images. This is of 
particular interest as evaluating changes on T1-weighted images is the current clinical 
standard for evaluating treatment response. More recent guidelines for evaluating treatment 
response such as the Response Assessment in Neuro-Oncology (RANO) evaluate T2-





used for clinical trial purposes [9]. This indicates that sodium images provide information 
beyond that of T1-weighted proton imaging, and that T2-weighted contrast may be more 
specific to tumour size. 
While our limited imaging was ultimately not able to discern between treatment 
and control groups, it is important to take into considerations the limitations and factors 
which impact this conclusion. Optimizing the model to be more sensitive to treatment could 
provide a way to better interrogate treatment effects on TSC changes. As mentioned 
previously, animals which received treatment experienced a more rapid decline due to the 
burden of chemotherapy in addition to the disease burden. This affected their overall 
survival and it is possible that animals were sacrificed before sodium changes could appear. 
Changing the timeline and method(s) of treatment for the animal model could potentially 
improve on this study. In a previous study by our group the same animal model was 
evaluated using magnetic resonance spectroscopic imaging of the metabolism of 
hyperpolarized [1-13C] pyruvate. Animals were placed into one of 4 groups receiving: no 
treatment, chemotherapy by TMZ, radiotherapy, and concurrent chemo-radiotherapy. It 
was observed that animals which received the concomitant chemo-radiotherapy had longer 
survival compared to administering each therapy individually or no therapy at all [10]. This 
indicates that treatment influences survival and this effect can be modulated by the choice 
of which treatment to prescribe. By extending the timeline and lessening the burden of 
treatment, animals in the treatment cohort could survive for a greater length of time, which 
could allow any effects due to treatment to be more clearly observable. A similar study 
conducted at 9.4T evaluated animals over a much longer timeline after treatment [11]. In 





grow for 17 days prior to a single treatment session with carmustine (BCNU). Animals 
were monitored for up to 30 days after treatment began. Through this extended timeline, 
an increase in TSC was observed until 5 days after treatment before a decrease was 
observed. Our results show a similar initial trend with increasing TSC however we 
ultimately were not able to follow the animals for an extended period after treatment. Given 
the shorter treatment duration compared to our study, it would be expected these animals 
received less therapeutic burden and that contributed to there improved survival.  
The Warburg effect describes the altered cellular metabolism found in cancer cells. 
The major characteristic of this altered metabolism is the increase in glycolytic activity 
even in the presence of oxygen. This activity decreases the pH in the tumour 
microenvironment due to an increase in proton concentration. The electro-chemical 
exchange that occurs to rebalance the cell pH increases the local TSC inside the cancer 
cells [12-14]. This will reflect in changes in the intracellular and extracellular environment 
as the cells work to maintain electrochemical homeostasis. Ultimately our DA3DPR 
imaging is only sensitive to total TSC and not to specific sodium compartments. This 
dependence on the intracellular and extracellular compartment means that the observed 
TSC can be affected by any changes that may occur in these spaces such as changes in the 
extracellular sodium concentration and the relative volumes of these two compartments 
[7].   
It is also important to recognize the impact of PVE on this study. Due to the large 
voxel size and reliance on segmentations based on anatomical proton images to obtain 
tumour TSC measurements, there are important considerations regarding the impact of 





segmented voxels may contain sodium measurements from areas both inside and outside 
of the tumour. This ultimately impacts the accuracy and measurement uncertainty 
associated with the sodium observations. This challenge is likely to persist in applications 
involving sodium MR due to current the inherent spatial resolution associated with using 
spherical k-space trajectories and the rapid signal relaxation [15].  
Sodium MRI has applications as a clinical molecular imaging modality due to its 
comparative ease of implementation compared to other molecular imaging techniques. 
Currently most of the research into preclinical sodium MRI occurs at high field strengths 
[11, 16]. While high field MR research has limited applicability to clinical translation, 
studies at lower fields have been conducted on humans [3, 4, 17]. These studies tend to 
focus on evaluating if TSC differences can be quantified for different disease states such 
as multiple sclerosis, hypertension, and diabetes [18-20]. Experimental work for 
interrogating specific applications and biomolecular relationships will still rely on 
preclinical imaging.  
In conclusion, this study has successfully implemented a quantifiable DA3DPR 
imaging protocol for orthotopic C6 rat glioma and was able to characterize changes in the 
tumour TSC over time and between brain regions. Relationships between tumour growth 
rate and TSC was observed as well as better characterization of the relationship between 
sodium signal and tumour morphology based on T1- and T2-weighted images. As this study 
is a preliminary study, we saw no differences between the treated and non-treated groups. 
Future work for this study will include improving the animal model to allow for a longer 
experimental timeline as well as expanding the size of the groups for increased statistical 





manifest and improve overall survival in the cohorts. As mentioned previously, our 
research group has previously studied this model with animal cohorts which also 
underwent radiotherapy and concurrent chemo-radiotherapy. Including these treatment 
cohorts in a future sodium MR study would improve our understanding of how TSC can 
be affected by different treatment methods. This could also provide insight into more 
clinically relevant treatment responses as the standard of care for GBM includes concurrent 
chemo-radiotherapy. Lastly, the ability to move birdcage coils independent of the sodium 
coils introduces the opportunity to study the relationship sodium and proton imaging may 
have with other molecular MR markers such as hyperpolarized 13C-labelled metabolites. 
This would provide additional molecular imaging metrics to observe the relationship 
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This thesis highlights the opportunities and challenges associated with the use of 
sodium MRI for assessment of pre-clinical tumours. An imaging protocol was optimized 
for a pilot investigation of changes in sodium in a preclinical treatment model of 
glioblastoma. Sodium levels were demonstrated to be sensitive to tumour growth in a C6 
GBM rat model. However, the model itself presented challenges when investigating the 
differences in TSC when treatment is applied. The main scientific contributions of this 
work will be summarized below.  
4.1 Summary and conclusions 
For this thesis, a new imaging sequence for sodium was introduced to our facilities 
and optimized for in vivo imaging using a surface coil. This protocol was then applied to 
investigate the use of sodium MRI for evaluating a preclinical C6 GBM rat model. This 
work began with overcoming the challenges associated with the implementation of the 
DA3DPR sequence and understanding the limitations of what was achievable given our 
equipment. This involved tuning and matching the sodium surface coil while loaded with 
a phantom and examining the performance of the coil over repeated imaging experiments. 
Ultimately, the protocol was optimized for imaging in clinical imaging mode at 3mm 
isotropic resolution. The use of a shift reagent and reference vials allowed for repeatable 





profile. This permitted extraction of absolute measurements of the in vivo tissue sodium 
concentration throughout the entire rat head.  
Longitudinal animal imaging experiments evaluated changes in TSC over time 
between a non-treated group (control) and a treatment group which received chemotherapy 
in the form of TMZ. These experiments showed that TSC increased over time as it was 
correlated with tumour growth. TSC within the tumour increased with both tumour volume 
and growth rate. No differences were ultimately found between the non-treated group and 
the treatment group when examining effects of treatment on TSC. Imaging was also able 
to clearly differentiate between tumour TSC and TSC in the tumour free contralateral brain 
region at endpoint. While TSC in the tumours was not significantly different between 
groups there was a slight difference in doubling time in the treatment group compared to 
the non-treatment group, with the treatment group having a slightly greater doubling time 
although this difference was not significant.  
In summary, this study demonstrated the feasibility of sodium MRI for pre-clinical 
research. An imaging pipeline for sodium MRI and image processing was established and 
longitudinal imaging was evaluated. This study showed that sodium MRI offers 
complementary information to clinical MR scans typically used for evaluating GBM. 
Sodium imaging was able to characterize some difference between CE T1-weighted images 
and T2-weighted images and has potential to be sensitive to tumour growth. Overall, there 
is potential for sodium MRI to be a useful molecular imaging biomarker for cancer in 





 4.1.1 Limitations 
There were several limitations which affect the conclusions that can be drawn from 
the results of this study. First it is important to note that there was no longitudinal histology 
to validate changes observed in the proton or sodium MR. Histology for time matched 
longitudinal points (at each imaging session) would have provided the gold standard 
against which, imaging results could be validated. It’s important to note that the endpoint 
histology presented here is most likely obtained when the tumour is the largest on the 
imaging and therefore the most visible. Being able to more concretely correlate tumour 
morphology to histology at earlier time points would have strengthened our understanding 
of the reliability of sodium MR. However, to acquire this data would have required large 
numbers of animals, been time-consuming, and costly.  
The limited sample size (n=7) for this study made it difficult to draw firm 
conclusions or differentiate if observed trends were significant. This is also significant 
considering the large biological variation observed from individual animals with regards 
to tumour progression. Increasing sample size would increase the statistical power for the 
analyses and allow for concrete conclusions to be drawn regarding trends and patterns 
observed within and between non-treatment and treatment groups.  
The experimental timeline that we chose from a previous imaging study ultimately 
resulted in difficulty observing treatment effects for this work. A high number of cells (106) 
were initially injected into the animal and allowed to grow over time. This resulted in a 
more rapid timeline for disease progression as well as more aggressive tumour growth. The 
treatment regime was unable to successfully combat the tumour burden, and the effects of 





animals’ post-treatment to determine if treatment had any long-term effects on TSC.  By 
improving the experimental protocol/timeline and allowing for a slower disease 
progression it is likely that post-treatment survival time could be increased, and treatment 
effects might be more clearly observed. The effect of a prolonged timeline has been 
observed in a slightly different model at higher field strengths. By decreasing the number 
of cells initially injected and increasing the length of the experiment, they were able to 
follow animals in the treatment cohort over the course of 45 days [1]. This is much longer 
even compared to results from a hyperpolarized 13C imaging study which used this same 
animal model and an expanded treatment regimen where survival was only observed to an 
average of 18 days [2].   
It is also important to recognize the limitations inherent to sodium MRI presented 
by the hardware and the modality itself. The resolution for the sodium imaging was 3mm 
isotropic at a field strength of 3T. It should be noted that this is similar to what other 
researchers have achieved at this field strength for in vivo imaging. In the context of a rat 
brain which is approximately 600mm3, this leaves an average of 200 pixels for the brain 
[3]. This resolution limits the comparison we can draw between the anatomical references 
and the sodium images as smaller areas in the higher resolution T1-weighted and T2-
weighted proton images will not be quantifiable in the sodium images. Quantification using 
sodium imaging is additionally limited due to PVE due to the relative pixel to tumour size. 
Taking into consideration regions of tumour visible on proton scans and not visible on 
sodium due to voxel size differences, as well as voxels at the boarder of the tumour which 
capture sodium signal both from tumorous and non-tumorous brain regions. Improvements 





possible with more SNR-efficient sequences or imaging at higher field strengths. It should 
be noted that increasing SNR at higher field strengths is ultimately limited in terms of 
applicability as such applications cannot be replicated in humans and TSC in rodent and 
other mammal tissues is similar to that in humans. 
4.1.2 Future work 
Future work for this study would include improvements to the pre-clinical model 
which would allow animals to be evaluated over longer periods of time. This would 
ultimately allow for the determination of any potential changes to TSC impacted by 
treatment. Furthermore, the addition of treatment groups in addition to stand-alone 
chemotherapy could lead to a more clinically relevant study. Current standard of care for 
GBM includes concurrent chemo-radiotherapy. By including animal groups which receive 
a combination of chemo-radiotherapy compared to those individual therapies could 
improve our understanding of how TSC changes in response to different therapies. Further 
work could include patient derived xenograft (PDX) models for GBM. As the cancer in 
these models would be derived from patients, they are more likely to recapitulate the 
biological behaviour of the tumours in humans and are more likely to respond to treatment 
similar to clinical response [4-6]. 
The addition of other molecular imaging techniques to our imaging can 
complement the information we learn from sodium MRI. Modalities such as PET or 
magnetic resonance spectroscopic imaging (MRSI) of hyperpolarized 13C metabolites can 
provide additional information specific to the metabolic characteristics of the tumour as 
well as the environment within and surrounding the tumour [2]. The combination of 





environment combined with information gained from sodium MRI would provide new 
insight into understanding the relationship between these techniques as well as gaps 
between the metabolic characteristics and the morphological characteristics proffered by 
anatomical T1-weighted or T2-weighted imaging.  
4.1.3 Significance and impact  
It is important to recognize the challenges that GBM poses for disease management. 
It is difficult to treat, requiring aggressive therapies and current clinical practices have not 
evolved significantly in over a decade [7]. Improving diagnostic and quantitative 
techniques provide new avenues for interrogating treatment response and tumour biology. 
The development of sodium MRI and its improvements has applications for a variety of 
diseases and conditions [8-10]. Sodium is the second most bio-available nucleus suitable 
for MR imaging and provides information related to the biochemistry of the cells rather 
than solely the morphology. By implementing the ability to obtain sodium and proton MR 
images at 3T we demonstrate the potential this modality has for more applications at 
clinical field strengths. In conclusion, this thesis provides a baseline for future longitudinal 
animal studies looking to incorporate sodium MRI into studies of treatment response and 
evaluating what information can be derived from multi-nuclear imaging at a more clinically 
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Appendix B. – Sodium surface coil intensity correction 
MATLAB script 
Read Sensitivity Map 
load nMap.mat 
load mP.mat 
Read Test Image 
I = double(niftiread('RatSodium.nii.gz'));           % Phantom 
IM=double(niftiread('RatSodium.mask.nii.gz'));   % Mask 
 
%I = imgaussfilt(I, 20); 
 





IM=imerode(IM,se1); % erode mask 
 
% The final Mask is the AND function of the image mask and the sensitivity mask 
Mask=IM.*mP; 
MI=I.*Mask; 
Display Test Image 





% Display final Mask 





% Display masked image 





% Display Sensitivity Map 
























Obtain the noise level 
%restrict to the first 18 slices 
mask2 = Mask(:,:,1:18); % addressed the PSF by grabbing everything from slices that don't 
contain vials 
I2 = I(:,:,1:18); 
 
Inv_Mask=1-mask2; % 0's where the object is, -1 everywhere else 
 
Inv_Mask=imerode(Inv_Mask,se2); % erode into the noise space (big) 
 
indx=find(Inv_Mask); % returns all non-zero indicies 
 
noise_level=mean(I2(indx)); % uses those indices to find the mean noise from the original 
image 
 





Obtain Image with Sensitivity Compensation 
%subtract offset from image 
MI = MI - noise_level; 
MI(MI<=0) = 0; 
 
































% Localize the vials 
indx_c=find_conc; 
 





















% Zero cross 
b=mdl.Coefficients.Estimate(1); 
 
% Obtain equation to get curve Concentration vs. Signal Intensity 
% Slope 
m2=1/m; 
% Zero cross 
b2=-b/m; 
 
values = linspace(0,100); 
 











Obtain Concentration Map 
C_Image=Mask.*(m2.*ISC+b2); 
C_Image(C_Image<=0)=0; 














    stdev_c(i)=std(final_stats.VoxelValues{i}); 












Validate fit from concentration map 
Localize the vials 
indx_c=find_conc; 
 





















% Zero cross 
b3=mdl2.Coefficients.Estimate(1); 
 
values = linspace(0,100); 
 






Function needed to match reference vials to correct concentration 
function indx=find_conc; 
figure(15) % Just to bring to the front the Region I.D. figure 
 
d = dialog('Position',[300 300 250 150],'Name','Select One'); 
txt = uicontrol('Parent',d,'Style','text','Position',[20 110 210 40],... 
    'String','Select the correct index for each vial with the given concentrations'); 
txt.FontSize=12; 
 
c1_txt=uicontrol('Parent',d,'Style','text','Position',[70 90 50 20],... 
    'String','30 mM','HorizontalAlignment','right'); 
c1_edit=uicontrol('Parent',d,'Style','edit','Position',[120 95 50 
15],'Callback',@edit_c1); 
 
c2_txt=uicontrol('Parent',d,'Style','text','Position',[70 75 50 20],... 
    'String','50 mM','HorizontalAlignment','right'); 
c2_edit=uicontrol('Parent',d,'Style','edit','Position',[120 80 50 
15],'Callback',@edit_c2); 
 
c3_txt=uicontrol('Parent',d,'Style','text','Position',[70 60 50 20],... 
    'String','70 mM','HorizontalAlignment','right'); 
c3_edit=uicontrol('Parent',d,'Style','edit','Position',[120 65 50 
15],'Callback',@edit_c3); 
 
c4_txt=uicontrol('Parent',d,'Style','text','Position',[70 45 50 20],... 
    'String','100 mM','HorizontalAlignment','right'); 
c4_edit=uicontrol('Parent',d,'Style','edit','Position',[120 50 50 
15],'Callback',@edit_c4); 
 
btn = uicontrol('Parent',d,... 
           'Position',[89 15 70 25],... 
           'String','Close',... 








    function edit_c1(c1_edit,event) 
        indx(1)=str2num(c1_edit.String); 
    end 
 
    function edit_c2(c2_edit,event) 
        indx(2)=str2num(c2_edit.String); 
    end 
 
    function edit_c3(c3_edit,event) 
        indx(3)=str2num(c3_edit.String); 
    end 
 
    function edit_c4(c4_edit,event) 
        indx(4)=str2num(c4_edit.String); 
    end 
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